Brett Jonathan, Knock Elizabeth, Korthuis P Todd, Liknaitzky Paul, Murnane Kevin S, Nicholas Christopher R, Patterson James C, Stauffer Christopher S
Department of Clinical Pharmacology, St. Vincent's Hospital, Sydney, NSW, Australia.
School of Population Health, Medicines Intelligence Centre of Research Excellence, University of New South Wales, Sydney, NSW, Australia.
Front Psychiatry. 2023 Mar 14;14:1123424. doi: 10.3389/fpsyt.2023.1123424. eCollection 2023.
Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality. Contingency management and psychotherapy interventions are the mainstays of treatment but are modestly effective with high relapse rates, while pharmacological treatments have shown little to no efficacy. Psilocybin-assisted psychotherapy is emerging as a promising treatment for a range of difficult-to-treat conditions, including substance use disorders; however, no studies have yet been published looking at psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Here we review the rationale for psilocybin-assisted psychotherapy as a potential treatment for this indication, and describe practical considerations based on our early experience designing and implementing four separate clinical trials of psilocybin-assisted psychotherapy for methamphetamine use disorder.
甲基苯丙胺使用障碍是一种慢性复发性疾病,会造成严重的精神、身体和社会危害,死亡率也在不断上升。应急管理和心理治疗干预是治疗的主要手段,但效果一般且复发率高,而药物治疗几乎没有效果。裸盖菇素辅助心理治疗正在成为治疗一系列难治性疾病(包括物质使用障碍)的一种有前景的治疗方法;然而,尚未有研究发表探讨裸盖菇素辅助心理治疗在甲基苯丙胺使用障碍治疗中的应用。在此,我们回顾将裸盖菇素辅助心理治疗作为该适应症潜在治疗方法的理论依据,并根据我们早期设计和实施四项裸盖菇素辅助心理治疗甲基苯丙胺使用障碍独立临床试验的经验描述实际注意事项。